Poland’s Quiet Pivot From Generics To Innovative Treatments

Poland’s biopharma sector is best known for its strengths in generics and biosimilars, with companies like Polpharma SA providing central Europe and beyond with a reliable flow of affordable off-patent medications. However, some established companies are now developing innovative medicines, and a small list of biotech companies are creating the groundwork for a nascent biotech ecosystem.

The shift towards an innovative medicines sector has been gradual. Some generic drug manufacturers, like Celon Pharma S.A., have built a hybrid business model that preserves their established focus with a foray into innovation